The FDA has expanded the approval of Rhapsido (remibrutinib) to include symptomatic dermographism in adults inadequately controlled by H1 antihistamines, backed by phase 3 RemIND trial data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results